ATE372770T1 - Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten - Google Patents

Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten

Info

Publication number
ATE372770T1
ATE372770T1 AT03766118T AT03766118T ATE372770T1 AT E372770 T1 ATE372770 T1 AT E372770T1 AT 03766118 T AT03766118 T AT 03766118T AT 03766118 T AT03766118 T AT 03766118T AT E372770 T1 ATE372770 T1 AT E372770T1
Authority
AT
Austria
Prior art keywords
treatment
diseases
respond
compounds useful
angiogenic therapy
Prior art date
Application number
AT03766118T
Other languages
English (en)
Inventor
Jens Lichtenberg
Palle Christophersen
Bjarne Dahl
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE372770T1 publication Critical patent/ATE372770T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Electrotherapy Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03766118T 2002-08-01 2003-07-31 Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten ATE372770T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DKPA200300371 2003-03-11

Publications (1)

Publication Number Publication Date
ATE372770T1 true ATE372770T1 (de) 2007-09-15

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766118T ATE372770T1 (de) 2002-08-01 2003-07-31 Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten

Country Status (17)

Country Link
US (1) US20060058395A1 (de)
EP (1) EP1526851B1 (de)
JP (1) JP2005537336A (de)
KR (1) KR20050026091A (de)
CN (1) CN1671378A (de)
AT (1) ATE372770T1 (de)
AU (1) AU2003260280A1 (de)
BR (1) BR0312929A (de)
CA (1) CA2493253A1 (de)
DE (1) DE60316297T2 (de)
IL (1) IL166040A0 (de)
IS (1) IS7723A (de)
MX (1) MXPA05001235A (de)
NO (1) NO20051074L (de)
NZ (1) NZ537809A (de)
PL (1) PL375318A1 (de)
WO (1) WO2004012733A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81664C2 (ru) 2003-06-17 2008-01-25 Ньюросерч А/С Производные дифенилмочевины и их применение, как блокаторов хлоридных каналов
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
AU2006206611A1 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
WO2006085302A2 (en) * 2005-02-08 2006-08-17 Bmz Diagnosis (2004) Ltd. Composition for treatment of skin disorders
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
WO2007002635A2 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2009054878A2 (en) * 2007-09-11 2009-04-30 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
SI3458052T1 (sl) * 2016-05-17 2020-04-30 Scandion Oncology A/S Kombinirano zdravljenje raka
EP3846802A1 (de) * 2018-09-06 2021-07-14 Scandion Oncology A/S Harnstoffderivate zur verwendung bei der behandlung von personen mit erhöhter expression und/oder aktivität von srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0809492A4 (de) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 rezeptor antagonisten
CN1118462C (zh) * 1997-04-22 2003-08-20 神经研究公司 取代的苯基衍生物、其制备方法以及用途
EP1049664B1 (de) * 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
SK5222001A3 (en) * 1998-10-22 2002-05-09 Neurosearch As Substituted phenyl derivatives, their preparation and use
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
ATE543497T1 (de) * 2002-07-09 2012-02-15 Bristol Myers Squibb Co Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren

Also Published As

Publication number Publication date
NZ537809A (en) 2007-05-31
WO2004012733A2 (en) 2004-02-12
EP1526851B1 (de) 2007-09-12
JP2005537336A (ja) 2005-12-08
WO2004012733A9 (en) 2005-03-10
WO2004012733A3 (en) 2004-03-18
DE60316297T2 (de) 2008-06-19
CN1671378A (zh) 2005-09-21
DE60316297D1 (de) 2007-10-25
IL166040A0 (en) 2006-01-15
MXPA05001235A (es) 2005-06-08
US20060058395A1 (en) 2006-03-16
EP1526851A2 (de) 2005-05-04
BR0312929A (pt) 2005-07-12
PL375318A1 (en) 2005-11-28
NO20051074L (no) 2005-04-29
AU2003260280A1 (en) 2004-02-23
IS7723A (is) 2005-03-01
CA2493253A1 (en) 2004-02-12
KR20050026091A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
DE60316297D1 (de) Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
DE60309739D1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
ATE403657T1 (de) Chemische verbindungen
EP1353672A4 (de) Synthese von 3-aminothalidomid und seinen enantiomeren
BR0318383A (pt) derivados de pirazoloisoquinolina como inibidores de cinase
ATE430742T1 (de) Pyrimidinamine als angiogenesemodulatoren
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DE602004022633D1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
ATE365165T1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
WO2005023815A3 (en) Neuroprotective bicyclic compounds and methods for their use
MX392158B (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
DE60308699D1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
ECSP003707A (es) Diazepanes
DE60222286D1 (de) Verfahren zur erhöhung des testosteronspiegels

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties